Intestinal cholesterol absorption, treatment with atorvastatin, and cardiovascular risk in hemodialysis patients

Journal of the American College of Cardiology

Volumn 65, Issue 21, 2015, Pages 2291-2298

  Silbernagel, Günther ^a   Fauler, Günter ^b   Genser, Bernd ^c,d,e   Drechsler, Christiane ^f   Krane, Vera ^f   Scharnagl, Hubert ^b   Grammer, Tanja B ^d   Baumgartner, Iris ^a   Ritz, Eberhard ^c   Wanner, Christoph ^f   März, Winfried ^c,g  

^a UNIVERSITY OF BERN   (Switzerland)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^e BGStats Consulting   (Austria)

^f UNIVERSITY OF WÜRZBURG   (Germany)

^g SYNLAB ACADEMY   (Germany)

Author keywords

cholestanol; mortality; randomized controlled trial; statin

Indexed keywords

ATORVASTATIN; BIOLOGICAL MARKER; CHOLESTANOL; CHOLESTEROL; PLACEBO; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRROLE DERIVATIVE;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GERMANY; HEMODIALYSIS PATIENT; HUMAN; INTESTINE ABSORPTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POST HOC ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; RISK REDUCTION; BLOOD; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; COMPLICATION; KIDNEY FAILURE, CHRONIC; METABOLISM; MIDDLE AGED; RENAL REPLACEMENT THERAPY;

AGED; CARDIOVASCULAR DISEASES; CHOLESTANOL; CHOLESTEROL; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTESTINAL ABSORPTION; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PYRROLES; RENAL DIALYSIS;

EID: 84930012255     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2015.03.551     Document Type: Article

References (25)

1. Cholesterol Treatment Trialists' (CTT) Collaborators B. Mihaylova, J. Emberson, and L. Blackwell The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials Lancet 380 2012 581 590
2. M. Tonelli, C. Isles, G.C. Curhan, and A. Tonkin Effect of pravastatin on cardiovascular events in people with chronic kidney disease Circulation 110 2004 1557 1563
3. P.M. Ridker, J. MacFadyen, M. Cressman, and R.J. Glynn Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial J Am Coll Cardiol 55 2010 1266 1273
4. J. Shepherd, J.J. Kastelein, and V. Bittner Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study J Am Coll Cardiol 51 2008 1448 1454
5. W. Hou, J. Lv, and V. Perkovic Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis Eur Heart J 34 2013 1807 1817
6. A. Upadhyay, A. Earley, J.L. Lamont, S. Haynes, C. Wanner, and E.M. Balk Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis Ann Intern Med 157 2012 251 262
7. C. Wanner, V. Krane, W. März for the German Diabetes and Dialysis Study Investigators Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis N Engl J Med 353 2005 238 248
8. B.C. Fellström, A.G. Jardine, R.E. Schmieder for the AURORA Study Group Rosuvastatin and cardiovascular events in patients undergoing hemodialysis N Engl J Med 360 2009 1395 1407
9. M.R. Kahn, M.J. Robbins, M.C. Kim, and V. Fuster Management of cardiovascular disease in patients with kidney disease Nat Rev Cardiol 10 2013 261 273
10. G. Silbernagel, I. Baumgartner, C. Wanner, and W. März Toward individualized cholesterol-lowering treatment in end-stage renal disease J Ren Nutr 24 2014 65 71
11. K.S. Rogacev, T. Pinsdorf, and O. Weingärtner Cholesterol synthesis, cholesterol absorption, and mortality in hemodialysis patients Clin J Am Soc Nephrol 7 2012 943 948
12. D.S. Mackay, and P.J. Jones Plasma non cholesterol sterols: current uses, potential and need for standardization Curr Opin Lipidol 23 2012 241 247
13. G. Silbernagel, M.J. Chapman, and B. Genser High intestinal cholesterol absorption is associated with cardiovascular disease and risk alleles in ABCG8 and ABO: evidence from the LURIC and YFS cohorts and from a meta-analysis J Am Coll Cardiol 62 2013 291 299
14. C. Wanner, V. Krane, and W. März Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics Kidney Blood Press Res 27 2004 259 266
15. G. Silbernagel, G. Fauler, and M.M. Hoffmann The associations of cholesterol metabolism and plasma plant sterols with all-cause and cardiovascular mortality J Lipid Res 51 2010 2384 2393
16. P. Andersen, and R. Gill Cox's regression model for counting processes, a large sample study Ann Stat 10 1982 1100 1120
17. J.K. Grønnesby, and O. Borgan A method for checking regression models in survival analysis based on the risk score Lifetime Data Anal 2 1996 315 328
18. A.S. Go, G.M. Chertow, D. Fan, C.E. McCulloch, and C.Y. Hsu Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization N Engl J Med 351 2004 1296 1305
19. R.T. Gansevoort, R. Correa-Rotter, and B.R. Hemmelgarn Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention Lancet 382 2013 339 352
20. M. Tonelli, C. Wanner Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline Ann Intern Med 160 2014 182 189
21. T.A. Miettinen, H. Gylling, T. Strandberg, and S. Sarna Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian Simvastatin Survival Study. Finnish 4S Investigators BMJ 316 1998 1127 1130
22. N.R. Matthan, M. Pencina, and J.M. LaRocque Alterations in cholesterol absorption/synthesis markers characterize Framingham offspring study participants with CHD J Lipid Res 50 2009 1927 1935
23. C. Baigent, M.J. Landray, C. Reith for the SHARP Investigators The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial Lancet 377 2011 2181 2192
24. N.D. Vaziri, and K.C. Norris Reasons for the lack of salutary effects of cholesterol-lowering interventions in end-stage renal disease populations Blood Purif 35 2013 31 36
25. D.S. Mackay, P.J. Jones, S.B. Myrie, J. Plat, and D. Lütjohann Methodological considerations for the harmonization of non-cholesterol sterol bio-analysis J Chromatogr B Analyt Technol Biomed Life Sci 957C 2014 116 122